Golimumab Shows Sustained Efficacy in Ankylosing Spondylitis Over ... - DG News

Live-PR.com (Pressemitteilung)

Golimumab Shows Sustained Efficacy in Ankylosing Spondylitis Over ... DG News By Bruce Sylvester COPENHAGEN, Denmark -- June 16, 2009 -- Patients with ankylosing spondylitis successfully treated with golimumab for 24 weeks have shown sustained treatment efficacy through week 104, researchers reported here at the 10th Annual ... Stakeholder Insight - Spondyloarthropathies - Disease perception ... Live-PR.com (Pressemitteilung) Golimubab Shows Long-Term Efficacy in Treatment of Psoriatic ... DG News all 3 news articles

EULAR: Five-Year Data Show Continued Benefit for Infliximab in AS - MedPage Today

EULAR: Five-Year Data Show Continued Benefit for Infliximab in AS MedPage Today, NJ By John Gever, Senior Editor, MedPage Today COPENHAGEN, June 22 -- Patients with ankylosing spondylitis (AS) generally maintained the clinical responses to infliximab (Remicade) seen during a two-year randomized trial for three more years, ...

Reducing Work Disability in Ankylosing Spondylitis - Development ... - 7thSpace Interactive (press release)

Reducing Work Disability in Ankylosing Spondylitis - Development ... 7thSpace Interactive (press release), NY The study objective was to explore the concept of Work Instability (a mismatch between an individual's abilities and job demands) in Ankylosing Spondylitis (AS) and develop a Work Instability Scale specific to this population. ...

Patients With Ankylosing Spondylitis Benefit from IFX Anti-TNF Therapy - MedIndia

MedIndia

Patients With Ankylosing Spondylitis Benefit from IFX Anti-TNF Therapy MedIndia, India After five years of receiving infliximab (IFX) anti-TNF therapy, 61.8% of patients with ankylosing spondylitis (AS) showed substantial clinical benefit (ASAS40, ASsessment in AS, 40-response) and 27.6% achieved ASAS partial remission. ...